# A Phase 1/2 Trial of ADI-270 in ccRCC

> **NCT06480565** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Adicet Therapeutics** · enrollment: 60 (estimated)

## Conditions studied

- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** ADI-270
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT06480565
- **Lead sponsor:** Adicet Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-12
- **Primary completion:** 2026-06
- **Final completion:** 2027-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06480565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06480565, "A Phase 1/2 Trial of ADI-270 in ccRCC". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06480565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*